46 studies found for:    "Adrenocortical carcinoma"
Show Display Options
RSS Create an RSS feed from your search for:
"Adrenocortical carcinoma"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed
Has Results
Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery
Conditions: Recurrent Adrenocortical Carcinoma;   Stage III Adrenocortical Carcinoma;   Stage IV Adrenocortical Carcinoma
Intervention: Drug: R-(-)-gossypol acetic acid
2 Terminated
Has Results
IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery
Conditions: Recurrent Adrenocortical Carcinoma;   Stage III Adrenocortical Carcinoma;   Stage IV Adrenocortical Carcinoma
Interventions: Biological: IMC-A12;   Drug: mitotane
3 Active, not recruiting Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor
Conditions: Stage I Adrenocortical Carcinoma;   Stage II Adrenocortical Carcinoma;   Stage III Adrenocortical Carcinoma;   Stage IV Adrenocortical Carcinoma
Interventions: Drug: doxorubicin hydrochloride;   Procedure: conventional surgery;   Drug: cisplatin;   Drug: mitotane;   Drug: etoposide;   Biological: filgrastim
4 Recruiting Surgery and Heated Chemotherapy for Adrenocortical Carcinoma
Conditions: Adrenocortical Carcinoma;   Peritoneal Carcinomatosis
Interventions: Procedure: Surgical resection and debulking;   Procedure: Heated intraperitoneal chemotherapy;   Drug: Cisplatin
5 Completed Trial With Taxotere and Cisplatin in Non-operable Adrenocortical Carcinoma
Condition: Adrenocortical Carcinoma
Intervention: Drug: cisplatin, taxotere
6 Recruiting Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma
Conditions: Adrenocortical Carcinoma;   Adrenal Cancer;   ACC
Intervention: Drug: ATR-101
7 Completed A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma
Condition: Adrenocortical Carcinoma
Interventions: Drug: OSI-906;   Other: Placebo
8 Active, not recruiting Clinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma
Condition: Adrenocortical Carcinoma
Intervention: Drug: Dovitinib
9 Completed Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
Conditions: Advanced Adult Primary Liver Cancer;   Anaplastic Thyroid Cancer;   Bone Metastases;   Carcinoma of the Appendix;   Distal Urethral Cancer;   Fallopian Tube Cancer;   Gastrinoma;   Glucagonoma;   Inflammatory Breast Cancer;   Insulinoma;   Liver Metastases;   Localized Unresectable Adult Primary Liver Cancer;   Lung Metastases;   Male Breast Cancer;   Malignant Pericardial Effusion;   Malignant Pleural Effusion;   Metastatic Gastrointestinal Carcinoid Tumor;   Metastatic Parathyroid Cancer;   Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter;   Newly Diagnosed Carcinoma of Unknown Primary;   Occult Non-small Cell Lung Cancer;   Pancreatic Polypeptide Tumor;   Primary Peritoneal Cavity Cancer;   Proximal Urethral Cancer;   Pulmonary Carcinoid Tumor;   Recurrent Adenoid Cystic Carcinoma of the Oral Cavity;   Recurrent Adrenocortical Carcinoma;   Recurrent Adult Primary Liver Cancer;   Recurrent Anal Cancer;   Recurrent Bladder Cancer;   Recurrent Breast Cancer;   Recurrent Carcinoma of Unknown Primary;   Recurrent Cervical Cancer;   Recurrent Colon Cancer;   Recurrent Endometrial Carcinoma;   Recurrent Esophageal Cancer;   Recurrent Extrahepatic Bile Duct Cancer;   Recurrent Gallbladder Cancer;   Recurrent Gastric Cancer;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Islet Cell Carcinoma;   Recurrent Malignant Testicular Germ Cell Tumor;   Recurrent Mucoepidermoid Carcinoma of the Oral Cavity;   Recurrent Non-small Cell Lung Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Pancreatic Cancer;   Recurrent Parathyroid Cancer;   Recurrent Prostate Cancer;   Recurrent Rectal Cancer;   Recurrent Renal Cell Cancer;   Recurrent Salivary Gland Cancer;   Recurrent Small Intestine Cancer;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Thyroid Cancer;   Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter;   Recurrent Urethral Cancer;   Recurrent Vaginal Cancer;   Recurrent Vulvar Cancer;   Skin Metastases;   Small Intestine Adenocarcinoma;   Somatostatinoma;   Stage III Adenoid Cystic Carcinoma of the Oral Cavity;   Stage III Adrenocortical Carcinoma;   Stage III Bladder Cancer;   Stage III Cervical Cancer;   Stage III Colon Cancer;   Stage III Endometrial Carcinoma;   Stage III Esophageal Cancer;   Stage III Follicular Thyroid Cancer;   Stage III Gastric Cancer;   Stage III Malignant Testicular Germ Cell Tumor;   Stage III Mucoepidermoid Carcinoma of the Oral Cavity;   Stage III Ovarian Epithelial Cancer;   Stage III Pancreatic Cancer;   Stage III Papillary Thyroid Cancer;   Stage III Prostate Cancer;   Stage III Rectal Cancer;   Stage III Renal Cell Cancer;   Stage III Salivary Gland Cancer;   Stage III Squamous Cell Carcinoma of the Larynx;   Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage III Squamous Cell Carcinoma of the Nasopharynx;   Stage III Squamous Cell Carcinoma of the Oropharynx;   Stage III Vaginal Cancer;   Stage III Vulvar Cancer;   Stage IIIA Anal Cancer;   Stage IIIA Breast Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Anal Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Adenoid Cystic Carcinoma of the Oral Cavity;   Stage IV Adrenocortical Carcinoma;   Stage IV Anal Cancer;   Stage IV Bladder Cancer;   Stage IV Breast Cancer;   Stage IV Colon Cancer;   Stage IV Endometrial Carcinoma;   Stage IV Esophageal Cancer;   Stage IV Follicular Thyroid Cancer;   Stage IV Gastric Cancer;   Stage IV Mucoepidermoid Carcinoma of the Oral Cavity;   Stage IV Non-small Cell Lung Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Pancreatic Cancer;   Stage IV Papillary Thyroid Cancer;   Stage IV Prostate Cancer;   Stage IV Rectal Cancer;   Stage IV Renal Cell Cancer;   Stage IV Salivary Gland Cancer;   Stage IV Squamous Cell Carcinoma of the Larynx;   Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IV Squamous Cell Carcinoma of the Nasopharynx;   Stage IV Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Cervical Cancer;   Stage IVA Vaginal Cancer;   Stage IVB Cervical Cancer;   Stage IVB Vaginal Cancer;   Stage IVB Vulvar Cancer;   Thyroid Gland Medullary Carcinoma;   Unresectable Extrahepatic Bile Duct Cancer;   Unresectable Gallbladder Cancer;   Urethral Cancer Associated With Invasive Bladder Cancer;   WDHA Syndrome
Interventions: Biological: recombinant interleukin-12;   Biological: ABI-007/carboplatin/trastuzumab
10 Completed Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC)
Condition: Nonresectable Adrenocortical Carcinoma
Intervention: Drug: Iressa (ZD1839)
11 Recruiting Natural History and Tissue Acquisition Study of Adrenocortical Carcinoma
Condition: Adrenocortical Carcinoma
Intervention:
12 Terminated S9427, Suramin in Treating Patients With Stage III or Stage IV Adrenocortical Cancer Incurable by Surgery
Condition: Adrenocortical Carcinoma
Interventions: Drug: suramin;   Drug: therapeutic hydrocortisone
13 Active, not recruiting Preclinical Study Towards an Immunotherapy in Adrenocortical Carcinoma
Conditions: Adrenocortical Carcinoma;   Cushing's Syndrome
Intervention:
14 Recruiting Cintredekin Besudotox (IL-13-PE) for Adrenocortical Carcinoma
Condition: Adrenocortical Carcinoma
Intervention: Drug: Cintredekin besudotox
15 Unknown  German Adrenocortical Carcinoma Registry
Condition: Adrenocortical Carcinoma
Intervention:
16 Unknown  Sunitinib in Refractory Adrenocortical Carcinoma
Condition: Adrenocortical Carcinoma
Intervention: Drug: Sunitinib
17 Withdrawn Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma
Condition: Adrenocortical Carcinoma
Intervention: Drug: Bevacizumab
18 Unknown  Sorafenib Plus Paclitaxel in Adreno-Cortical-Cancer Patients
Condition: Adrenocortical Carcinoma
Interventions: Drug: Sorafenib;   Drug: Paclitaxel
19 Recruiting A Study to Determine Safety, Pharmacokinetics and Pharmacodynamics of Intravenous TKM 080301 in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients
Conditions: Cancer;   Neuroendocrine Tumors;   NET;   Adrenocortical Carcinoma;   ACC
Intervention: Drug: TKM-080301
20 Completed A Study of Combination Chemotherapy and Surgical Resection in the Treatment of Adrenocortical Carcinoma: Continuous Infusion Doxorubicin, Vincristine and Etoposide With Daily Mitotane Before and After Surgical Resection
Condition: Adrenal Cortical Carcinoma
Intervention: Drug: doxorubicin, vincristine, and etoposide with mitotane

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years